中文摘要：

类风湿关节炎（rheumatoid arthritis,RA）是一种慢性、系统性的自身免疫性疾病,迄今病因尚不明确,且缺乏针对其安全有效的治疗药物。由于B淋巴细胞在RA致病机制中的重要作用,近年来不断有针对B淋巴细胞上不同靶点的治疗药物推出。这些B淋巴细胞靶向生物制剂包括针对CD20分子的抗CD20单克隆抗体,如rituximab、ocrelizumab和ofatumumab等;针对B淋巴细胞刺激因子（B lymphocyte stimulator,BLyS）及其受体的belimumab和atacicept等以及处于初期研究阶段的抗CD22单克隆抗体和B、T淋巴细胞之间CD40/CD40L共刺激反应阻断剂等。上述靶向制剂的疗效在对RA及其动物模型的治疗中得到了证实,提示将B淋巴细胞作为RA治疗靶点是一项非常有前景的治疗策略。

英文摘要：

Rheumatoid arthritis（RA） is a chronic and systemic autoimmune disease,it＇s pathogenic mechanism is unknown and there is a lack of safe and effective therapeutic drug on RA.Because of important function of B cells in RA pathogenic mechanism,many therapeutic drugs targeted on different positions of B cells are emerging in RA therapy.These B cell-targeted therapeutic biologic agents include anti-CD20 monoclonal antibody（such as rituximab,ocrelizumab and ofatumumab）,biologic agents which targeted B lymphocyte stimulator（BLyS） and their receptors（such as belimumab and atacicept）,anti-CD22 monoclonal antibody and CD40/CD40L co-stimulation reaction blocker.Efficacy of above-mentioned targeting agents has confirmed in studies of RA and it＇s animal models,suggesting that it is a promising therapeutic strategy that B cells are regarded as targeting position in RA therapy.